Taylor Jennie W, Warrier Gayathri, Hansen Helen M, McCoy Lucie, Rice Terri, Guerra Geno, Francis Stephen S, Clarke Jennifer L, Bracci Paige M, Hadad Sara, Kelsey Karl T, Wrensch Margaret, Molinaro Annette M, Wiencke John K
Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Department of Neurology, University of California San Francisco, San Francisco, California, USA.
Neurooncol Adv. 2024 Aug 19;6(1):vdae143. doi: 10.1093/noajnl/vdae143. eCollection 2024 Jan-Dec.
Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells.
We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival.
Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age ( = .00032). Patients with worse survival also had lower CD4- and CD8-naïve T-cells. Similar immune profiles were observed in an independent cohort of oligodendroglioma patients prior to surgery.
Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.
少突胶质细胞瘤患者生存情况的差异无法用已知的预后因素来解释。为了评估外周免疫特征对预后的影响，我们应用免疫甲基化组学分析——对存档的全血样本进行DNA甲基化分析，以表征免疫细胞。
我们将少突胶质细胞瘤患者的免疫细胞比例与其他胶质瘤亚型及对照组进行比较。我们在少突胶质细胞瘤患者中采用递归分割分析（RPA）来与生存情况进行关联。
141例少突胶质细胞瘤患者诊断时的中位年龄为44岁；57%为男性；75%为白人；60%曾接受化疗；样本采集时25%正在使用地塞米松。少突胶质细胞瘤患者的免疫特征比其他胶质瘤亚型更类似于对照组，不过B细胞明显较少。少突胶质细胞瘤患者的RPA根据年龄与初始B细胞之间的相互作用划分出两个生存组。生存时间较长（中位24.2年）的患者年龄≤42岁且初始B细胞较高，而生存情况较差（中位16.9年）的患者年龄≤42岁且初始B细胞较低或年龄>42岁（P = 0.00032）。生存情况较差的患者初始CD4和CD8 T细胞也较少。在一组独立的术前少突胶质细胞瘤患者队列中观察到了类似的免疫特征。
少突胶质细胞瘤患者的外周血免疫特征表明，初始B细胞较少的年轻患者生存时间较短。尽管我们的研究结果缺乏验证队列且使用的是异质性患者群体，但它们表明外周血免疫特征可能对胶质瘤患者具有预后价值，值得进一步研究。
